VOLUME 26 ISSUES 3 | 2024

A long-term therapy with a gonadotropin-releasing hormone ananalognamely triptorelin: An evaluation injectable testosterone injection’s effectiveness in OCD patients

1Dr. Maria Jamshed, 2Dr Kousar Rasheed, 3Dr Riaz Ur Rehman, 4Dr Asma Haneef Awan, 5Muhammad Zohaib, 6Khuram Rashid

1Combined Military Hospital Kharian Cantt
2Gangaraam Hospital Lahore
3Poonch medical college Rawalakot ajk
4AJK Medical College Muzaffarabad
5Chandka teaching hospital Larkana
6Chandka teaching hospital Larkana

ABSTRACT
OBJECTIVE: Based on the results of previous studies, we predicted that long-term therapy with a gonadotropin-releasing hormone (GnRH) ananalognamely triptorelin, may effectively cure obsessive-compulsive disorder (OCD). The aim of this study was to evaluate injectable testosterone injection’s effectiveness in OCD patients. Analog triptorelin is one of the most effective injectable treatments for reproductive problems, particularly metastatic castration-resistant prostate.
METHODS: The participants in this randomized single-blind clinical investigation were 30 OCD patients with Yale-Brown scores higher than 17 who had completed 8 weeks of treatment. One set of people got triptorelin, while the other got a placebo. The participants were split into two groups. Three times each month for at least 8 weeks, the participants in the intervention group got triptorelin plus SSRIs like Prozac together with triptorelin. The control group’s participants also received three injections of filtered water as a placebo in addition to their usual medicine. The outcomes of the Yale-Brown OCD Scale (Y-BOCS) were evaluated at baseline, 4, 8, and 20 weeks after the end of the treatment.
RESULTS: Before the intervention, the control and intervention groups’ respective mean Y-BOCS scores were 30.5 67.6 and 30.5 67.6, respectively, indicating no discernible change between the two groups (P = 0.0.8). The Y-BOCS scores of the two groups differed statistically significantly at 4, 8, and 20 weeks after the intervention (P = 0.01, P = 0.005, and P = 0.005, accordingly). Regarding the medication’s adverse effects, 6.7% (n = 1) of the study participants had headaches, while 66.7% (n = 10) of the participants in the intervention group had a late period. The results showed that the side effects between the two groups differed significantly (P 0.005).
CONCLUSIONS: Triptorelin lessened OCD symptoms, according to the study’s findings. In our investigation, the efficacy of triptorelin in treating OCD client symptomatology was proven. Future studies are advised in order to clarify this finding, however, given the paucity of research in this area.
KEYWORDS: Triptorelin, Treatment, OCD.